title: Cefaclor vs amoxicillin in the treatment of acute, recurrent, and chronic sinusitis.
abstract: BACKGROUND
  The treatment of acute, recurrent, and chronic sinusitis remains controversial because of the presence of a wide variety of aerobic and anaerobic bacteria in the sinuses.
  
  
  METHODS
  This double-blind, randomized trial compared cefaclor with amoxicillin in the treatment of acute, recurrent, and chronic maxillary sinusitis using clinical evaluation, roentgenography, and microbiologic evaluation of antral aspirates.
  
  
  METHODS
  Outpatient office of five otorhinolaryngologists in Salt Lake City, Utah.
  
  
  METHODS
  One hundred eight adult patients with acute, recurrent, or chronic maxillary sinusitis.
  
  
  METHODS
  Oral treatment with cefaclor (500 mg) twice daily or amoxicillin (500 mg) three times daily for 10 days.
  
  
  METHODS
  Clinical response to treatment with cefaclor vs amoxicillin.
  
  
  RESULTS
  Fifty-six patients with acute sinusitis, 25 with recurrent sinusitis, and 15 with chronic sinusitis were evaluable. Although multiple organisms were common in each group, patients with acute sinusitis were more likely to have Haemophilus influenzae or Streptococcus pneumoniae, and patients with recurrent or chronic sinusitis were more likely to have anaerobes in sinus aspirate. Whether treated with cefaclor or amoxicillin, clinical improvement occurred in 86% of patients with acute sinusitis and 56% of patients with recurrent sinusitis. Patients with chronic sinusitis were too few to allow statistical analysis of the differences in outcome between them and patients with recurrent or acute sinusitis. Resistance of the cultured organisms to the study drug used was unrelated to treatment outcome.
  
  
  CONCLUSIONS
  The rate of clinical improvement was high in patients with acute sinusitis but was less favorable in those with recurrent and chronic disease regardless of the study drug used. The susceptibility of organisms isolated to the study drugs was unrelated to outcome.
authors.affiliation: Advanced Clinical Microbiology/Research, Salt Lake City, Utah.
authors.forename: W
authors.initials: W
authors.lastname: Huck
authors.forename: B D
authors.initials: BD
authors.lastname: Reed
authors.forename: R W
authors.initials: RW
authors.lastname: Nielsen
authors.forename: R T
authors.initials: RT
authors.lastname: Ferguson
authors.forename: D W
authors.initials: DW
authors.lastname: Gray
authors.forename: G K
authors.initials: GK
authors.lastname: Lund
authors.forename: D H
authors.initials: DH
authors.lastname: ZoBell
authors.forename: M B
authors.initials: MB
authors.lastname: Moster
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D002433:Cefaclor / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D006801:Humans; D015523:Maxillary Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D012008:Recurrence
chemical_list: D002433:Cefaclor; D000658:Amoxicillin